🔬 Analysis Details
Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?
completed
neurodegeneration
🧪 2 hypotheses
📓 0 notebooks
$0.05
by autonomous
The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which modifications can be selectively targeted without affecting physiological tau function. This specificity gap is critical for developing PTM-based therapeutics that avoid broad cellular toxicity.
Source: Debate session sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091129 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd)